Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
therapeutic allogeneic lymphocytes
- Development stage
- Phase 3
- Lead developer
- Allogene Therapeutics
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Therapeutic allogeneic lymphocytes are a form of adoptive cell therapy (ACT) where T lymphocytes from a donor are collected, expanded, and potentially engineered before being transferred to a recipient to eliminate pathogens and/or cancer cells. This therapy harnesses the graft-versus-leukemic or graft-versus-tumor effect, where donor lymphocytes recognize certain antigens on cancer cells and eliminate tumor cells. Unlike traditional hematopoietic cell transplantation, allogeneic cell therapy can function as 'universal effector cells' and potentially be used as an 'off-the-shelf' cellular therapy for cancer treatment.
- Other names
- therapeutic ex vivo-expanded allogeneic gamma delta T cells
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on therapeutic allogeneic lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on therapeutic allogeneic lymphocytes.